The lower target of <6.5% in selected instances is supported by the evidence that hypoglycemia in patients with T2DM receiving insulin is rare [18] and A1C > 6.3% after 3 months of metformin or any increasing A1C even in the non-diabetes range was associated with increased risk for loss of glycemic control in the TODAY study [10]. Here, INS is linked to type 2 diabetes mellitus.